FDA Commissioner Marty Makary advocates for more prescription drugs to be available over-the-counter (OTC), aiming to reduce costs and increase accessibility, while also planning to change drug approval standards by requiring only one rigorous study instead of two, which could accelerate new drug availability. This shift emphasizes modern scientific precision but may face skepticism from the pharmaceutical industry; content creators should monitor these regulatory changes for potential impacts on healthcare coverage and public health discussions.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
Views9
Tags
Ali NematiBlogUI.author_articles
